Thumbnail Image
Publication

Experimental Drugs for the Treatment of Hepatitis D.

Sandmann, Lisa
; 
Cornberg, Markus
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2021-04-16
Submitted date
Show all metadata
Files
Thumbnail Image
Open Access article
Adobe PDF, 408.99 KB
Other Titles
Abstract
Chronic hepatitis D virus infection is the most severe form of viral hepatitis. Antiviral treatment is urgently needed to prevent patients from developing end stage liver disease or hepatocellular carcinoma. Treatment options were limited to off-label use of pegylated interferon alfa until conditional approval of bulevirtide by the EMA (European Medicines Agency) in July 2020. However, several other antiviral compounds are currently investigated and represent promising agents for the treatment of chronic HDV infection.
Citation
J Exp Pharmacol. 2020 Nov 16;12:503-515. doi: 10.2147/JEP.S273120.
Affiliation
CiiM, Zentrum für individualisierte Infektionsmedizin, Feodor-Lynen-Str.7, 30625 Hannover.
Publisher
Dovepress
Journal
Journal of experimental pharmacology
URI
http://hdl.handle.net/10033/622896
DOI
10.2147/JEP.S235550
PubMed ID
33889032
PubMed Central ID
Additional Links
Embedded video
Type
Review
Language
en
Description
Series/Report no.
ISSN
1179-1454
EISSN
ISBN
ISMN
Gov't Doc #
Sponsors
License
Attribution 4.0 International
cb
Collections
publications of the working group of computational biology for individualized medicine ([CiiM] BIIM)